A rare but potentially catastrophic obstetrical complication, placenta accreta is on the increase, given the current trend toward elective repeat C/S. Three experts detail the best approach to management, which begins with antenatal ultrasound diagnosis.
Tebipenem HBr cUTI trial ends early after meeting efficacy goals
May 28th 2025GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.
Read More